Home > Courses > Persistent Low-level Viremia in HIV Management: What Is It? When Should We Worry?

Persistent Low-level Viremia in HIV Management: What Is It? When Should We Worry?

Sorry, this learning module is not available for mobile devices.

Watch this Learning Module

COLLABORATION STATEMENT: The AIDS Institute is proud of the ongoing collaboration between the Clinical Education Initiative (CEI) and Physicians Research Network (PRN). Founded in 1990, PRN has a well-established reputation for spotlighting the work of the most innovative and influential leaders in the HIV treatment, prevention and research fields through its monthly meetings in New York City. Since 2010, CEI has featured recordings of PRN's monthly events through the CEI website. The combined efforts of both educational institutions have enhanced the continuing educational resources available to New York State clinicians caring for people living with, or at risk for HIV.

Original Release Date: 12/17/2019

Termination Date: 12/16/2022

Review Date: 3/9/2020

Presenter

Daniel R Kuritzkes, MD
Professor
Harvard Medical School

Learning Objectives / Desired Outcomes

At the completion of this educational activity, participants will:

Know how to define persistent low-level viremia and differentiate it from early HIV treatment failure.
Understand the mechanisms of persistent low-level viremia.
Be able to provide guidance for management of patients with persistent low-level viremia.

Presenter Bio

Daniel R. Kuritzkes received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection, has chaired several multicenter studies of HIV therapy, and currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group. He is a member of the NIH Office of AIDS Research Advisory Council, and serves as an Associate Editor of the Journal of Infectious Diseases. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.

Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on December 17, 2019 and will terminate December 16, 2022.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.

Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Daniel R. Kuritzkes, MD (Presenter) had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research Support from Abbvie, Gilead, Merck, and ViiV; Consultant to Gilead, GlaxoSmithKline, Merck, and ViiV; Speaking Honorarium from Janssen. Dr. Kurtizkes submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details:

This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

PRN Learning Modules